Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver: a Randomized, Double-blinded, Placebo-controlled Trial

NCT07637006 is registered in ClinicalTrials.gov with Hong Kong Baptist University as lead sponsor.

NCT NCT07637006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07637006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver: a Randomized, Double-blinded, Placebo-controlled Trial
Lead sponsor
Hong Kong Baptist University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
January 31, 2029
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated fatty liver disease (mafld)